Allergic contact dermatitis (ACD) may complicate the clinical course of atopic dermatitis (AD), and patch testing remains the criterion standard for diagnosing ACD. To date, there have been no guidelines or consensus recommendations on when and how to patch test individuals with AD. Failure to patch test when appropriate may result in overlooking an important and potentially curable complicating comorbidity. In this article, we present consensus recommendations regarding when to perform patch testing in the AD patient, best practices, and common pitfalls. Patch testing should be considered in AD patients with dermatitis that fails to improve with topical therapy; with atypical/changing distribution of dermatitis, or pattern suggestive of ACD; with therapy-resistant hand eczema in the working population; with adult- or adolescent-onset AD; and/or before initiating systemic immunosuppressants for the treatment of dermatitis. A suggested patch testing algorithm for AD patients is provided.
Get full access to this article
View all access options for this article.
References
1.
EliasPM, HatanoY, WilliamsML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol, 2008; 121(6):1337–1343.
2.
GittlerJK, KruegerJG, Guttman-YasskyE. Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol, 2013; 131(2):300–313.
3.
JacobSE, GoldenbergA, NedorostS, et al.Flexural eczema versus atopic dermatitis. Dermatitis, 2015; 26(3):109–115.
4.
ManMQ, HatanoY, LeeSH, et al.Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol, 2008; 128(1):79–86.
5.
NewellL, PolakME, PereraJ, et al.Sensitization via healthy skin programs Th2 responses in individuals with atopic dermatitis. J Invest Dermatol, 2013; 133(10):2372–2380.
6.
SidburyR, TomWL, BergmanJN, et al.Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches. J Am Acad Dermatol, 2014; 71(6):1218–1233.
7.
FonacierL, BernsteinDI, PachecoK, et al.Contact dermatitis: a practice parameter-update 2015. J Allergy Clin Immunol Pract, 2015; 3(3Suppl):S1–S39.
8.
JohansenJD, Aalto-KorteK, AgnerT, et al.European Society of Contact Dermatitis guideline for diagnostic patch testing—recommendations on best practice. Contact Dermatitis, 2015; 73(4):195–221.
9.
de Waard-van der SpekFB, DarsowU, MortzCG, et al.EAACI position paper for practical patch testing in allergic contact dermatitis in children. Pediatr Allergy Immunol, 2015; 26(7):598–606.
10.
EichenfieldLF, HanifinJM, LugerTA, et al.Consensus conference on pediatric atopic dermatitis. J Am Acad Dermatol, 2003; 49(6):1088–1095.
11.
ThyssenJP, McFaddenJP, KimberI. The multiple factors affecting the association between atopic dermatitis and contact sensitization. Allergy, 2014; 69(1):28–36.
12.
DhingraN, ShemerA, Correa da RosaJ, et al.Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol, 2014; 134(2):362–372.
13.
UeharaM, SawaiT. A longitudinal study of contact sensitivity in patients with atopic dermatitis. Arch Dermatol, 1989; 125(3):366–368.
14.
Correa da RosaJ, MalajianD, ShemerA, et al.Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin. J Allergy Clin Immunol, 2015; 135(3):712–720.
15.
JakasaI, VerberkMM, EspositoM, et al.Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol, 2007; 127(1):129–134.
16.
EichenfieldLF, TomWL, BergerTG, et al.Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol, 2014; 71(1):116–132.
17.
HamannCR, BernardS, HamannD, et al.Is there a risk using hypoallergenic cosmetic pediatric products in the United States?. J Allergy Clin Immunol, 2015; 135(4):1070–1071.
18.
MailholC, Lauwers-CancesV, RanceF, et al.Prevalence and risk factors for allergic contact dermatitis to topical treatment in atopic dermatitis: a study in 641 children. Allergy, 2009; 64(5):801–806.
19.
SeoKS, ParkJY, TermanDS, et al.A quantitative real time PCR method to analyze T cell receptor Vbeta subgroup expansion by staphylococcal superantigens. J Transl Med, 2010; 8:2.
20.
HuangL, KinbaraM, FunayamaH, et al.The elicitation step of nickel allergy is promoted in mice by microbe-related substances, including some from oral bacteria. Int Immunopharmacol, 2011; 11(11):1916–1924.
21.
TakahashiH, KinbaraM, SatoN, et al.Nickel allergy-promoting effects of microbial or inflammatory substances at the sensitization step in mice. Int Immunopharmacol, 2011; 11(10):1534–1540.
22.
NassifA, ChanSC, StorrsFJ, et al.Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol, 1994; 130(11):1402–1407.
23.
WhitmoreSE. Should atopic individuals be patch tested?. Dermatol Clin, 1994; 12(3):491–499.
24.
ThyssenJP, JohansenJD, LinnebergA, et al.The association between contact sensitization and atopic disease by linkage of a clinical database and a nationwide patient registry. Allergy, 2012; 67(9):1157–1164.
25.
ThyssenJP, LinnebergA, EngkildeK, et al.Contact sensitization to common haptens is associated with atopic dermatitis: new insight. Br J Dermatol, 2012; 166(6):1255–1261.
26.
CarlsenBC, AndersenKE, MenneT, et al.Characterization of the polysensitized patient: a matched case-control study. Contact Dermatitis, 2009; 61(1):22–30.
27.
SchwitullaJ, GefellerO, SchnuchA, et al.Risk factors of polysensitization to contact allergens. Br J Dermatol, 2013; 169(3):611–617.
28.
ShaughnessyCN, MalajianD, BelsitoDV. Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis: reactivity to topical preservatives. J Am Acad Dermatol, 2014; 70(1):102–107.
29.
PaulsenE, AndersenKE. Sensitization patterns in Compositae-allergic patients with current or past atopic dermatitis. Contact Dermatitis, 2013; 68(5):277–285.
30.
WarshawEM, NelsenDD, MaibachHI, et al.Positive patch test reactions to lanolin: cross-sectional data from the north american contact dermatitis group, 1994 to 2006. Dermatitis, 2009; 20(2):79–88.
31.
ThyssenJP, CarlsenBC, MenneT, et al.Filaggrin null mutations increase the risk and persistence of hand eczema in subjects with atopic dermatitis: results from a general population study. Br J Dermatol, 2010; 163(1):115–120.
32.
Vind-KezunovicD, JohansenJD, CarlsenBC. Prevalence of and factors influencing sensitization to corticosteroids in a Danish patch test population. Contact Dermatitis, 2011; 64(6):325–329.
33.
ShaughnessyCN, MalajianD, BelsitoDV. Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis: reactivity to surfactants. J Am Acad Dermatol, 2014; 70(4):704–708.
34.
Tamagawa-MineokaRMK, UedaS, NakamuraN, et al.Contact sensitivity in patients with recalcitrant atopic dermatitis. J Dermatol, 2015; 42:720–722.
35.
CzarnobilskaE, ObtulowiczK, DygaW, et al.A half of schoolchildren with ’ISAAC eczema’ are ill with allergic contact dermatitis. J Eur Acad Dermatol Venereol, 2011; 25(9):1104–1107.
36.
MagnussonLL, WennborgH, BondeJP, et al.Wheezing, asthma, hay fever, and atopic eczema in relation to maternal occupations in pregnancy. Occup Environ Med, 2006; 63(9):640–646.
37.
PuangpetP, Lai-CheongJ, McFaddenJP. Chemical atopy. Contact Dermatitis, 2013; 68(4):208–213.
38.
WilliamsJ, CahillJ, NixonR. Occupational autoeczematization or atopic eczema precipitated by occupational contact dermatitis?. Contact Dermatitis, 2007; 56(1):21–26.
39.
JacobSE, BurkCJ, ConnellyEA. Patch testing: another steroid-sparing agent to consider in children. Pediatr Dermatol, 2008; 25(1):81–87.
40.
FowlerJF Jr, MaibachHI, ZirwasM, et al.Effects of immunomodulatory agents on patch testing: expert opinion 2012. Dermatitis, 2012; 23(6):301–303.
41.
JacobSE, AdmaniS, HerroEM. Invited commentary: recommendation for a North American pediatric patch test series. Curr Allergy Asthma Rep, 2014; 14(6):444.
42.
SchwensenJF, JohansenJD. p-Phenylenediamine and risk of sensitization in children. Curr Treat Options Allergy, 2014; 1(3):299–309.
43.
MortzCG, Bindslev-JensenC, AndersenKE. Nickel allergy from adolescence to adulthood in the TOACS cohort. Contact Dermatitis, 2013; 68(6):348–356.
44.
BraschJ, SchnuchA, UterW. Patch-test reaction patterns in patients with a predisposition to atopic dermatitis. Contact Dermatitis, 2003; 49(4):197–201.
45.
KligmanAM. The myth of lanolin allergy. Contact Dermatitis, 1998; 39(3):103–107.
46.
WentworthAB, DavisMD. Patch testing with the standard series when receiving immunosuppressive medications. Dermatitis, 2014; 25(4):195–200.
47.
GeierJ, UterW, PirkerC, et al.Patch testing with the irritant sodium lauryl sulfate (SLS) is useful in interpreting weak reactions to contact allergens as allergic or irritant. Contact Dermatitis, 2003; 48(2):99–107.
48.
HigginsE, CollinsP. The relevance of 7-day patch test reading. Dermatitis, 2013; 24(5):237–240.
49.
IsakssonM, AndersenKE, BrandaoFM, et al.Patch testing with corticosteroid mixes in Europe. A multicentre study of the EECDRG. Contact Dermatitis, 2000; 42(1):27–35.
50.
DavisMD, BhateK, RohlingerAL, et al.Delayed patch test reading after 5 days: the Mayo Clinic experience. J Am Acad Dermatol, 2008; 59(2):225–233.
51.
VillaramaCD, MaibachHI. Correlations of patch test reactivity and the repeated open application test (ROAT)/provocative use test (PUT). Food Chem Toxicol, 2004; 42(11):1719–1725.
52.
NakadaT, HostynekJJ, MaibachHI. Use tests: ROAT (repeated open application test)/PUT (provocative use test): an overview. Contact Dermatitis, 2000; 43(1):1–3.
53.
KerschenlohrK, DarsowU, BurgdorfWH, et al.Lessons from atopy patch testing in atopic dermatitis. Curr Allergy Asthma Rep, 2004; 4(4):285–289.
